Compare CGEM & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGEM | BRSP |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.7M | 683.8M |
| IPO Year | 2021 | 2018 |
| Metric | CGEM | BRSP |
|---|---|---|
| Price | $10.76 | $5.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $28.00 | $6.00 |
| AVG Volume (30 Days) | ★ 1.4M | 721.2K |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | N/A | ★ 10.79% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $330,894,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.68 | $4.16 |
| 52 Week High | $13.33 | $6.41 |
| Indicator | CGEM | BRSP |
|---|---|---|
| Relative Strength Index (RSI) | 52.87 | 73.78 |
| Support Level | $10.01 | $5.60 |
| Resistance Level | $13.10 | $5.97 |
| Average True Range (ATR) | 1.04 | 0.11 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 25.57 | 92.71 |
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.